{"schema_version":"1.0","type":"article","title":"Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check","url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.md","lang":"en","date":"2026-06-12","publish_at":"2026-06-12T10:30:00+08:00","updated_at":"2026-06-12","category":"商業分析系列","topic":"商業分析系列","tags":["AI drug discovery","Clinical pipelines","Biotech investing","Business development","Drug development","Big Pharma"],"summary":"AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets.","key_points":[],"facts":[],"sections":["Reading AI Drug Discovery Through Pipelines: Models Are Hot, But the Real Question Is Who Enters the Clinic","01 | Zasocitinib: Using Computational Chemistry to Bring TYK2 Into Phase 3","02 | GB-0895: Generative AI Antibodies Begin to Challenge Long-Acting Biologics","03 | Zovegalisib: AI Can Find Molecules, But It Can Also See Hidden Pockets in Protein Dynamics","04 | REC-4881: AI Does Not Always Need to Invent a New Drug; It Can Also Find a New Use for an Old One","05 | What These Pipelines Show: AI Drug Discovery Is Not One Model, But Four Different Capabilities","06 | The Real Question for AI Drug Discovery: Not Whether a Model Can Generate Molecules, But Whether Those Molecules Can Survive the Human Test","07 | Why Big Pharma Is Willing to Pay: AI May Improve R&D Capital Efficiency","Conclusion | AI Drug Discovery Is No Longer Just a Trend; It Is Entering the Exam Period"],"references":[{"title":"[0]: Company websites and public disclosures","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"YouTube","source":"","date":"","url":""},{"title":"Takeda today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2","source":"","date":"","url":""},{"title":"www.takeda.com","source":"","date":"","url":""}],"images":[{"alt":"AI drug discovery pipeline map with Zasocitinib, GB-0895, Zovegalisib, and REC-4881","url":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/figure-01-ai-pipeline-en.png"},{"alt":"Four core capabilities behind AI drug discovery","url":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/figure-02-ai-capabilities-en.png"},{"alt":"AI drug discovery from model hype to clinical asset value","url":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/figure-03-ai-asset-value-en.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/cover-ai-drug-discovery.jpg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-12）。Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check。https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-12-ai-drug-discovery-pipeline-20260612.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}